MX2009001070A - Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. - Google Patents

Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.

Info

Publication number
MX2009001070A
MX2009001070A MX2009001070A MX2009001070A MX2009001070A MX 2009001070 A MX2009001070 A MX 2009001070A MX 2009001070 A MX2009001070 A MX 2009001070A MX 2009001070 A MX2009001070 A MX 2009001070A MX 2009001070 A MX2009001070 A MX 2009001070A
Authority
MX
Mexico
Prior art keywords
melanoma
mia
concentration
inhibitory activity
biological sample
Prior art date
Application number
MX2009001070A
Other languages
English (en)
Inventor
Carla Heise
Nguyen Tan
Eleni Venetsanakos
Michel Faure
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009001070A publication Critical patent/MX2009001070A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

La presente invención proporciona un método para determinar una respuesta de un sujeto mamífero que tiene células de tumor de melanoma al tratamiento con un agente inhibidor de melanoma. En un aspecto, el método comprende (a) determinar una primera concentración de la Proteína con Actividad Inhibidora de Melanoma (MIA) en una primera muestra biológica tomada del sujeto mamífero antes del tratamiento con el agente inhibidor de melanoma; (b) determinar una segunda concentración de MIA en una segunda muestra biológica del sujeto mamífero tomada después del tratamiento con el agente inhibidor de melanoma, y (c) comparar la primera y la segunda concentraciones de MIA, en donde una disminución en la segunda concentración de MIA medida en la segunda muestra biológica en comparación con la primera concentración de MIA medida en la primera muestra biológica indica una respuesta positiva al tratamiento con el agente inhibidor de melanoma.
MX2009001070A 2006-07-28 2007-07-26 Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. MX2009001070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82075606P 2006-07-28 2006-07-28
PCT/US2007/016848 WO2008013912A1 (en) 2006-07-28 2007-07-26 Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma

Publications (1)

Publication Number Publication Date
MX2009001070A true MX2009001070A (es) 2009-04-23

Family

ID=38626977

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001070A MX2009001070A (es) 2006-07-28 2007-07-26 Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.

Country Status (11)

Country Link
US (2) US8288087B2 (es)
EP (1) EP2049904A1 (es)
JP (2) JP5274458B2 (es)
KR (1) KR20090046893A (es)
CN (1) CN101512343A (es)
AU (1) AU2007277144B2 (es)
BR (1) BRPI0715062A2 (es)
CA (1) CA2659270A1 (es)
MX (1) MX2009001070A (es)
RU (1) RU2480769C2 (es)
WO (1) WO2008013912A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124413A2 (en) 2005-05-13 2006-11-23 Novartis Ag Methods for treating drug resistant cancer
MX2009009574A (es) * 2007-03-09 2009-09-16 Novartis Ag Tratamiento de melanoma.
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
WO2011044072A1 (en) * 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
US20170184602A1 (en) * 2014-04-24 2017-06-29 Pfizer Inc. Cancer treatment
JP2019507352A (ja) * 2015-12-02 2019-03-14 クリアライト ダイアグノスティックス リミテッド ライアビリティ カンパニー 癌の検出およびモニタリングのための腫瘍組織サンプルの調製および分析のための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725538A (en) * 1985-10-25 1988-02-16 The Beth Israel Hospital Association Method of assaying the presence of cancer cells
DE69033295T2 (de) * 1989-11-03 2000-05-25 Donald L Morton Nachweismethode für Harnkarzinom-assoziierte Antigene
CA2167693C (en) * 1993-07-20 2007-01-30 Ulrich Bogdahn Melanoma-inhibiting protein
US5869332A (en) * 1994-06-03 1999-02-09 Southwest Foundation For Biomedical Research Metastatic melanoma cell lines from monodelphis domestica for use in anti-cancer agent discovery
DE602004026341D1 (de) * 2003-11-04 2010-05-12 Bayer Pharmaceuticals Corp IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN
RU2280483C2 (ru) * 2004-07-05 2006-07-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ определения эффективности противоопухолевого лечения меланом кожи
US20090311174A1 (en) * 2005-07-21 2009-12-17 Barry John Allen Method For Treating Cancer

Also Published As

Publication number Publication date
US8288087B2 (en) 2012-10-16
RU2480769C2 (ru) 2013-04-27
EP2049904A1 (en) 2009-04-22
JP2013083665A (ja) 2013-05-09
WO2008013912A1 (en) 2008-01-31
AU2007277144B2 (en) 2012-01-19
KR20090046893A (ko) 2009-05-11
JP2009544970A (ja) 2009-12-17
CA2659270A1 (en) 2008-01-31
JP5274458B2 (ja) 2013-08-28
RU2009106718A (ru) 2010-09-10
BRPI0715062A2 (pt) 2013-06-04
US20100009392A1 (en) 2010-01-14
AU2007277144A1 (en) 2008-01-31
CN101512343A (zh) 2009-08-19
US20130237546A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
TW200617380A (en) Concentration determination in a diffusion barrier layer
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
MX2010006484A (es) Composiciones y metodos para detectar anticuerpos de infidelidad de transcripcion (tiab).
TW200745543A (en) System and methods for providing corrected analyte concentration measurements
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
CA2726071A1 (en) Blood glucose monitoring device
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2008141282A3 (en) Materials and methods for foxp3 tumor suppression
ATE450547T1 (de) Eml4-alk-fusionsgen
WO2014170497A3 (en) Method for identifying the quantitative cellular composition in a biological sample
WO2011133668A3 (en) Methods and compositions for the treatment of cancer
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
WO2012056236A3 (en) Analytical methods and arrays for use in the identification of agents inducing sensitization in human skin
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
MX2014006118A (es) Deteccion de analitos.
WO2010033597A3 (en) Methods for detecting overexpression of sparc and therapeutic and diagnostic methods relating to same
EP2284526A4 (en) BIOSENSOR SYSTEM, SENSING POINT AND METHOD FOR MEASURING THE CONCENTRATION OF A SUBSTANCE TO BE ANALYZED IN A BLOOD SAMPLE
HK1133295A1 (en) Use of protein s100a12 as a marker for colorectal cancer s100a12
RU2009108662A (ru) Способ выявления остеогенных средств и способ стимуляции остеогенеза (варианты)
RU2014149089A (ru) Способ определения биологической активности дефибротида, основанный на применении эуглобулина
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
AU2018275891A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
WO2008074029A3 (en) Protein profile for osteoarthritis

Legal Events

Date Code Title Description
FG Grant or registration